新辅助化疗后保留乳房手术治疗进展期乳腺癌可行性分析

doi:10.11904/j.issn.1002-3070.2016.02.003

Abstract

Abstract: Objective To analyse the breast conserving surgery feasibility in patients with advanced breast cancer after neoadjuvant chemotherapy.Methods Sixty patients with advanced breast cancer were collected from June 2010 to June 2011,and were divided into breast conserving surgery after neoadjuvant chemotherapy group and modified radical mastectomy group according to the intention,30 cases in each group.They were given breast conserving surgery after neoadjuvant chemotherapy and modified radical mastectomy respectively,with following-up for 3 years.The treatment effect and contrast analysis of two groups of breast cancer CTCs positive of the two groups were compared,two groups of late follow-up of patients with local recurrence and distant metastasis rate,overall survival and disease free survival rate were recorded.Results Compared with the modified radical mastectomy group,CTCs detection rate in breast conserving surgery group had no statistical differences(P＞0.05).Two groups of patients in clinical complete remission rate,partial remission rate,disease stability factor and local recurrence and distant metastasis rate,overall survival and disease free survival rate had no statistical significances(P＞0.05).Conclusion The application of breast conserving surgery after neoadjuvant chemotherapy for patients with advanced breast cancer can achieve similar effect as modified radical mastectomy surgery treatment,and can be used as a effective treatment for advanced breast cancer.

Key words: Breast conserving surgery, Neoadjuvant chemotherapy, Advanced breast cancer, Feasibility analysis

CLC Number:

R737.9

DAI Meng, LI Rui, LIU Guiting, LIANG Jinlong, FENG Jinfa, XU Shanyong. The feasibility analysis of breast conserving surgery after neoadjuvant chemotherapy in the treatment with advanced breast cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 109-113.

References

1 Bonev V,Evangelista M,Chen JH,et al.Long-term follow-up of breast-conserving therapy in patients with inflammatory breast cancer treated with neoadjuvant chemotherapy[J].Am Surg,2014,80(10):940-943.
2 Matsuda N,Hayashi N,Ohde S,et al.A nomogram for predicting locoregional recurrence in primary breast cancer patients who received breast-conserving surgery after neoadjuvant chemotherapy[J].J Surg Oncol,2014,109(8):764-769.
3 Vergine M,Scipioni P,Garritano S,et al.Breast-conserving surgery after neoadjuvant chemotherapy in patients with locally advanced cancer.Preliminary results[J].G chir,2013,34(9/10):254-256.
4 Caudle AS,Kuerer HM.Breast conservation therapy after neoadjuvant chemotherapy:optimization of a multimodality approach[J].J Surg Oncol,2014,110(1):32-36.
5 Carpenter R,Doughty JC,Cordiner C.Optimum duration of neoadjuvant letrozole to permit breast conserving surgery[J].Breast Cancer Res Treat,2014,144(3):569-576.
6 Povoski SP,Jimenez RE,Wang WP,et al.Standardized and reproducible methodology for the comprehensive and systematic assessment of surgical resection margins during breast-conserving surgery for invasive breast cancer[J].BMC Cancer,2009,9:254.
7 Najafi YM,Ebrahimi YM,Kaviani YA,et al.Breast conserving surgery versus mastectomy:cancer practice by general surgeons in Iran[J].BMC Cancer,2005,5:35.
8 Madaras L,Kovács KA,Szász AM,et al.Clinicopathological features and prognosis of pregnancy associated breast cancer-a matched case control study[J].Pathol Oncol Res,2014,20(3):581-590.
9 郭贵龙,尤捷,陈学敏.乳腺癌的保乳治疗(附76例报告)[J].实用肿瘤学杂志,2007,21(6):532-535.
10 Nakamura S,Kenjo H,Nishio T,et al.3D-MR mammography-guided breast conserving surgery after neoadjuvant chemotherapy:clinical results and future perspectives with reference to FDG-PET[J].Breast Cancer,2001,8(4):351-354.
11 Inaji H,Komoike Y,Motomura K,et al.Breast-conserving treatment after neoadjuvant chemotherapy in large breast cancer[J].Breast Cancer,2002,9(1):20-25.
12 高影,程流泉,刘梅.MRI对局部进展期乳腺癌新辅助化疗早期疗效评价[J].中国医学影像学杂志,2012,20(5):321-324.
13 Mamounas EP.Impact of neoadjuvant chemotherapy on locoregional surgical treatment of breast cancer[J].Ann Surg Oncol,2015,22(5):1425-1433.
14 陈文有,刘静,毛顺宝.多西他赛+表阿霉素方案在乳腺癌新辅助化疗中的应用[J].山西医药杂志,2013,42(13):745-746.
15 白海亚,龚晓军,刘慧民.CD4+/CD8+在评价局部进展期乳腺癌新辅助化疗疗效中的应用价值[J].中国优生优育,2014,20(3):129-132.
16 Akashi-Tanaka S,Fukutomi T,Sato N,et al.The use of contrast-enhanced computed tomography before neoadjuvant chemotherapy to identify patients likely to be treated safely with breast-conserving surgery[J].Ann Surg,2004,239(2):238-243.
17 张勇,秦贤举,倪旭东.ⅢA期乳癌新辅助化疗后保乳手术的探讨[J].实用肿瘤学杂志,2004,18(2):114-115.
18 Julius T,Kemp SE,Kneeshaw PJ.MRI and conservative treatment of locally advanced breast cancer[J].Eur J Surg Oncol,2005,31(10):1129-1134.
19 Huober J,Krainick-Strobel U,Kurek R.Neoadjuvant endocrine therapy in primary breast cancer[J].Clin Breast Cancer,2004,5(5):341-347.

[1]	LI Yujiao, SHANG Naijian. Research progress of imaging evaluation of neoadjuvant chemotherapy in breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 63-67.
[2]	CHEN Li, ZHANG Yuxin, ZUO Yanjiao, MA Fei, SONG Hongjiang, XUE Yingwei. The comparison of clinical efficacy of SOX and XELOX in the neoadjuvant chemotherapy for advanced gastric carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 23-30.
[3]	LUO Hongyu, LI Jiaqi, LUAN Jinwei, ZHANG Siliang, LI Xianglan. The progress of radiotherapy in triple negative breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 180-183.
[4]	BA Zhichang, WANG Xinxin, CUI Wanhui, GUO Fei, ZHANG Xiushi. Value of diffusion weighted magnetic resonance imaging in the monitoring of neoadjuvant chemotherapy efficacy for uterine cervical cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(6): 518-522.
[5]	ZHU Hong,ZHU Li,HAN Shiyu,FANG Fang,YU Yang. The predictive value of DWI for progression free survival in patients with cervix cancer after neoadjuvant chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2014, 28(6): 519-523.
[6]	NING Siqing,ZHAN Botao,XU haisheng. The investigation of effects of TNP in the head and neck squamous cell carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2014, 28(6): 540-544.
[7]	SONG Yulin,WANG Jing. The screening and assessment of the neoadjuvant chemotherapy for the ovarian cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2014, 28(6): 553-556.
[8]	MA Rong,CHEN Xihai,GENG Xiaoxing,LIU Shuang,ZHANG Heng. The evaluation of effectiveness of concurrent chemoradiation for locally advanced cervical cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2012, 26(4): 314-318.
[9]	TENG Chong,SONG Xiaowei,CAI Li. Effect and clinical significance of Ki-67 in neoadjuvant chemotherapy for breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2012, 26(2): 188-192.
[10]	MO Xueli,WANG Delin,CAO Yujuan,DU Fang,CAO Feng,SUN Jianhua,LIU Chengwei,HAO Longying. Concurrent chemoradiotherapy with weekly Paclitaxol in advanced breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2011, 25(5): 437-438.
[11]	YIN Mingzhu,LOU Ge,CHEN Xiuwei,GU Taihua. The long-term efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with concurrent chemoradiotherapy on locally advanced uterine cervix cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2011, 25(1): 40-45.
[12]	WU Liangzhi, JIANG Nan, ZHANG Yi. Study on the molecule mechanisms efficacy of two kinds of neoadjuvant chemotherapy in locally and advanced cervix cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2009, 23(5): 427-429.
[13]	XU Ye, GAO Ying, LOU Ge. A clinical observation on neoadjuvant chemotherapy for ovary tumor of advanced stage treated with paclitaxel liposome and nedaplatin [J]. PRACTICAL ONCOLOGY JOURNAL, 2008, 22(6): 512-513.

The feasibility analysis of breast conserving surgery after neoadjuvant chemotherapy in the treatment with advanced breast cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 13

Recommended Articles

Metrics

Comments